Breaking News Instant updates and real-time market news.

LLY

Eli Lilly

$75.99

-0.65 (-0.85%)

06:52
11/23/16
11/23
06:52
11/23/16
06:52

Eli Lilly down 11% pre-market after solanezumab trial did not meet endpoint

Shares are down 11% to $67.45 in pre-market trading.

  • 04

    Dec

LLY Eli Lilly
$75.99

-0.65 (-0.85%)

11/03/16
BMOC
11/03/16
NO CHANGE
BMOC
Eli Lilly factored pricing pressure into guidance, says BMO Capital
After meeting with Eli Lilly, BMO Capital analyst Alex Arfaei reports that the company seemed surprised at the intensity of investors' concerns about pricing pressure on it. The analyst says that the company anticipated pricing pressure and factored it into its guidance. The analyst keeps a $91 price target and an Outperform rating on the shares.
11/09/16
SBSH
11/09/16
NO CHANGE
SBSH
Citi sees Healthcare 'relief rally' after Trump win
Citi analyst Andrew Baum expects a "'relief rally" to drive near-term sector outperformance for names in the Healthcare space given the "inability of the Democrats to attain the Presidency, the House or Congress." Longer term, however, the analyst still sees "significant continued legislative risk" for pharma reimbursement. Baum prefers GlaxoSmithKline (GSK), AstraZeneca (AZN), Shire (SHPG) and Roche (RHHBY) among European majors and Bristol-Myers (BMY) and Eli Lilly (LLY) in the U.S.
11/11/16
JEFF
11/11/16
NO CHANGE
Target $100
JEFF
Buy
Jefferies bullish on Lilly regardless of Alzheimer's data
Jefferies analyst Jeffrey Holford believes shares of Eli Lilly "can work over time" regardless of Alzheimer's disease drug solanezumab's Phase III study outcome. The analyst, however, says he has enough confidence to recommend Lilly shares ahead of the EXPEDITION3 data readout. Holford increased his base case solanezumab peak sales to $5B. He says Lilly remains one of his top picks with a Buy rating and $100 price target.
11/15/16
JPMS
11/15/16
NO CHANGE
Target $95
JPMS
Overweight
JPMorgan sees favorable risk/reward for Lilly into Alzheimer's data
JPMorgan analyst Chris Schott sees a favorable risk/reward profile for shares of Eli Lilly into the solanezumab data for Alzheimer's, which is expected by year-end. Favorable data from the EXPEDITION-3 trial would represent a catalyst not just for Lilly and other Alzheimer's associated names but for the biopharma space as a whole, Schott tells investors in a research note. The analyst expects 20%-plus share upside in the event the trial is successful on both primary and secondary endpoints. He assigns a 10%-20% probability to this outcome. Schott sees 10%-20% share upside for Lilly should the study hit on its primary but only shows a trend on secondary endpoints. He assigns a 50%-60% probability for this outcome. The analyst also sees a 10% move to the downside if the study fails both endpoints, an outcome he assigns a 20% probability. Schott reiterates an Overweight rating on Lilly with a $95 price target. He believes Lilly's "diverse range of pipeline opportunities" largely supports the valuation at current levels.

TODAY'S FREE FLY STORIES

FNB

F.N.B.

$15.52

-0.15 (-0.96%)

, YDKN

Yadkin Financial

$33.15

-0.415 (-1.24%)

12:03
02/24/17
02/24
12:03
02/24/17
12:03
Periodicals
Federal Reserve clears F.N.B.'s takeover of Yadkin, Reuters reports »

The Federal Reserve has…

FNB

F.N.B.

$15.52

-0.15 (-0.96%)

YDKN

Yadkin Financial

$33.15

-0.415 (-1.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVDA

NVIDIA

$100.49

-10.27 (-9.27%)

12:01
02/24/17
02/24
12:01
02/24/17
12:01
Options
Heavy trading in Nvidia short-term options as shares stage an aggressive rebound »

Heavy trading in Nvidia…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 05

    Mar

  • 16

    Mar

  • 20

    Mar

12:00
02/24/17
02/24
12:00
02/24/17
12:00
General news
Treasury Option Action: a round of put activity »

Treasury Option Action: a…

ONCS

OncoSec

$1.42

-0.1 (-6.58%)

11:59
02/24/17
02/24
11:59
02/24/17
11:59
Conference/Events
OncoSec to hold KOL Event Focused on New ASCO-SITC Melanoma Data »

OncoSec's Chief…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MGEN

Miragen Therapeutics

$13.99

-0.06 (-0.43%)

11:55
02/24/17
02/24
11:55
02/24/17
11:55
Hot Stocks
Boulder Ventures V reports 9.9% stake in Miragen Therapeutics »

According to a regulatory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTG

MGIC Investment

$10.55

-0.055 (-0.52%)

11:51
02/24/17
02/24
11:51
02/24/17
11:51
Options
MGIC Investment with 11.5X average daily optoin volume driven by a bullish play »

MGIC Investment with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WLL

Whiting Petroleum

$11.06

-0.09 (-0.81%)

11:46
02/24/17
02/24
11:46
02/24/17
11:46
Options
Whiting Petroleum call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

11:45
02/24/17
02/24
11:45
02/24/17
11:45
Conference/Events
Leerink analysts hold an analyst/industry conference call »

In conjunction with the…

11:40
02/24/17
02/24
11:40
02/24/17
11:40
General news
NY Fed Nowcast has Q1 GDP at 3.12% »

NY Fed Nowcast has Q1 GDP…

SPWR

SunPower

$8.99

0.53 (6.26%)

11:36
02/24/17
02/24
11:36
02/24/17
11:36
Options
SunPower put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IDRA

Idera Pharmaceuticals

$1.73

0.05 (2.98%)

11:33
02/24/17
02/24
11:33
02/24/17
11:33
Hot Stocks
Idera says achieved 'successful' completion of objectives in Phase 1 trial »

Idera Pharmaceuticals is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRIL

Trillium Therapeutics

$5.90

-0.1 (-1.67%)

11:32
02/24/17
02/24
11:32
02/24/17
11:32
Hot Stocks
Trillium Therapeutics: New TTI-621 data advances understanding of product »

Trillium Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VISI

Volt Information Sciences

$7.35

-0.1 (-1.34%)

, CCRN

Cross Country Healthcare

$15.89

-0.37 (-2.28%)

11:32
02/24/17
02/24
11:32
02/24/17
11:32
Hot Stocks
Volt Information Sciences reports nomination of new independent directors »

Volt Information Sciences…

VISI

Volt Information Sciences

$7.35

-0.1 (-1.34%)

CCRN

Cross Country Healthcare

$15.89

-0.37 (-2.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Mar

  • 08

    Mar

  • 14

    Mar

  • 21

    Mar

MCO

Moody's

$112.59

-0.64 (-0.57%)

11:31
02/24/17
02/24
11:31
02/24/17
11:31
Conference/Events
Leerink analysts hold an analyst/industry conference call »

Analysts provide a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Mar

  • 05

    Mar

VIVHY

Vivendi

$17.95

-0.06 (-0.33%)

, MDIUY

Mediaset

11:28
02/24/17
02/24
11:28
02/24/17
11:28
Periodicals
Milan prosecutors investigating Vivendi over alleged stock manipulation, FT says »

Milan prosecutors are…

VIVHY

Vivendi

$17.95

-0.06 (-0.33%)

MDIUY

Mediaset

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FSLR

First Solar

$37.19

3.62 (10.78%)

11:26
02/24/17
02/24
11:26
02/24/17
11:26
Options
First Solar call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Mar

GS

Goldman Sachs

$247.19

-4 (-1.59%)

11:23
02/24/17
02/24
11:23
02/24/17
11:23
Periodicals
Goldman Sachs exec involved in 1MDB dealings leaves bank, WSJ says »

A senior Goldman Sachs…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Mar

ALNY

Alnylam

$46.25

0.3 (0.65%)

11:22
02/24/17
02/24
11:22
02/24/17
11:22
Conference/Events
JPMorgan SMid biotech analyst holds an analyst/industry conference call »

SMid Biotech Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

$NSD

NASDAQ Market Internals

11:17
02/24/17
02/24
11:17
02/24/17
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

11:16
02/24/17
02/24
11:16
02/24/17
11:16
Technical Analysis
NYSE market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MBLY

Mobileye

$46.96

-1.18 (-2.45%)

11:16
02/24/17
02/24
11:16
02/24/17
11:16
Options
Mobileye put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

HBI

Hanesbrands

$20.96

0.04 (0.19%)

11:12
02/24/17
02/24
11:12
02/24/17
11:12
Conference/Events
Hanesbrands management to meet with Oppenheimer »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

WIX

Wix.com

$63.25

-2.3 (-3.51%)

11:10
02/24/17
02/24
11:10
02/24/17
11:10
Conference/Events
Wix.com management to meet with Oppenheimer »

Meetings to be held on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 01

    Mar

  • 02

    Mar

SNCR

Synchronoss

$30.86

-0.03 (-0.10%)

11:09
02/24/17
02/24
11:09
02/24/17
11:09
Periodicals
Synchronoss has withheld 'a great deal' about 'transformation,' SIRF says »

Synchronoss Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RXN

Rexnord

$22.05

-0.09 (-0.41%)

11:08
02/24/17
02/24
11:08
02/24/17
11:08
Conference/Events
Rexnord management to meet with Oppenheimer »

Meeting to be held in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

  • 01

    Mar

  • 07

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.